Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Aberrant, absolute, accidental, adjunct, ADM, alleviate, Altimmune, anticholinesterase, Appendix, APVO, ascending, assert, atropine, Attached, autoinjector, Bailey, Bayview, begun, BESP, biotechnology, Cape, cartridge, Century, chloride, CODM, compensatory, complaint, context, Coral, counsel, counter, criterion, Crowe, deficiency, District, Dowd, Dr, duly, EBOL, employment, enriched, EUND, Exhibit, extraction, Extraordinary, fall, Fargo, fever, FILOV, fourth, fragmented, Geller, German, Harsanyi, Hauer, hemorrhagic, hereto, herewith, Homeland, horse, IBT, IgG, indemnify, indeterminate, insecticide, insider, Intergen, intraperiod, IRS, isolated, jeopardized, Jerome, Jr, Kathryn, Language, lawsuit, Marburg, MCM, Meridian, Ministry, misleading, Motion, Municipal, NASDAQ, Neglected, Nonstatutory, notified, notwithstanding, obidoxime, obiltoxaximab, omitted, organizational, orthopox, pilot, Plaintiff, poisoning, Police, pralidoxime, precluded, preserve, pretax, prevail, prioritization, promissory, PRV, purported, rapidly, realigned, referenced, regime, reinstate, reissued, representation, resell, residual, retention, Revocable, Richard, Ronald, Rudman, shareholder, Singapore, situation, Specimen, Sponn, Sudan, sulfate, Sullivan, sulphate, Sunrise, supplementary, symptomatic, taxpayer, Tecovirimat, thereto, thereunder, thereunto, transition, transitional, transitioned, Trobigard, TrobigardTM, Tropical, unallocated, undersigned, unrealizable, unsecured, vendor, vi, VIG, vigorously, voluntary, voucher, William, XBRL, Zaire, zika, Zoon, Zsolt
Removed:
Abbott, abbvie, abnormally, absence, absorb, abuse, acre, acting, acute, ADAPTIR, ADAPTIRTM, adding, AG, aggressive, AlphaNine, Alprolix, American, AmerisourceBergen, Amgen, AMP, Antex, antigen, Apotex, Arzerra, ASP, augmented, autoimmune, BATTM, Baxter, Behring, bendamustine, beneficiary, Benefix, Biogen, BioPort, Bioscience, bioterrorist, Biotest, biowarfare, birth, bleeding, Boehringer, bone, borrowed, Bracco, built, cancer, Cardinal, carrier, categorized, ceased, ceiling, Cephalon, challenging, chemotherapy, chickenpox, child, children, chronic, clarified, clause, CLL, clotting, CMS, Coast, combat, commenced, commonly, community, complement, Concurrent, confer, consistency, Consortium, constructed, consuming, counted, counterterrorism, coupled, CSL, cutting, cycle, dba, dealing, deductible, deeply, depleting, destroyed, die, discovery, discrete, disproportionate, distinct, DVA, ease, Education, enforced, England, entitle, escalation, ESPP, exclusion, exclusively, female, fencing, financially, forma, formula, formulated, fraud, fraudulent, frequent, FSS, gas, Gayzva, Genentech, Genmab, Gilead, GmbH, handled, HDN, hemolytic, hemophilia, history, hospital, HPPD, HSBC, humanized, HyperHEP, Idec, Imbruvica, immunocompromised, ImmunoGen, improved, inappropriate, incidence, incident, incompatible, Indian, induce, industrial, inflation, Ingelheim, inherited, inhibitor, instituted, interface, invoiced, irreversible, ITP, Johnson, joint, Journal, Justice, kickback, knowingly, Kuwait, larger, launch, Leukemia, liver, Lymphocytic, lymphoma, managed, marrow, maternal, maximizing, McKesson, Medicaid, medically, Medicare, missing, modular, MonoNine, multinational, mustard, network, neutralization, newborn, noncontrolling, Nordisk, North, Novo, Nplate, obinutuzumab, offered, ordered, otlertuzumab, outpatient, Oxford, pain, participate, partner, patentable, penalty, penetration, percent, perimeter, pertaining, pharmacy, PHS, pivotal, platelet, PNC, pregnant, prepare, presenting, prevalence, pro, producing, proliferate, Promacta, prophylactic, protein, published, purpura, qualification, radiation, reach, Realty, rebate, recurrence, red, redeemed, referral, reinfection, relapsed, remuneration, renamed, renovation, reorganization, repaid, repay, reportable, reprioritization, restore, restored, retired, Rhophlac, Rituxan, rituximab, Roche, routine, SA, sBLA, science, scrutiny, Seattle, secret, selectively, serve, showed, side, Society, solicit, spontaneously, strength, strictly, sufficiency, surface, tangible, team, Teva, Therapex, thrombocytopenic, tolerated, toxic, transplant, transplantation, transportation, trauma, Treanda, Turkey, turnover, UK, uncontrolled, unnecessary, untreated, USA, validating, Vaxin, vector, violate, Washington, weapon, willingly, women, worldwide
Filing tables
Filing exhibits
Related press release
EBS similar filings
Filing view
External links
EXHIBIT 23
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-139190) pertaining to the Employee Stock Option Plan, as amended and restated, the 2006 Stock Incentive Plan and individual director options agreements of Emergent BioSolutions, Inc., |
(2) | Registration Statement (Form S-8 No. 333-161154) pertaining to the Employee Stock Option Plan, as amended and restated, and the 2006 Stock Incentive Plan of Emergent BioSolutions, Inc., |
(3) | Registration Statement (Form S-4 No. 333-169351) of Emergent BioSolutions Inc. and Subsidiaries, |
(4) | Registration Statement (Form S-3 No. 333-181133) of Emergent BioSolutions Inc. and Subsidiaries, |
(5) | Registration Statement (Form S-8 No. 333-184699) pertaining to the 2012 Employee Stock Option Plan and the Second Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, |
(6) | Registration Statement (Form S-8 No. 333-196232) pertaining to the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, and |
(7) | Registration Statement (Form S-3 No. 333-204405) of Emergent BioSolutions Inc. and Subsidiaries; |
of our reports dated February 27, 2017, with respect to the consolidated financial statements and schedule of Emergent BioSolutions Inc. and subsidiaries and the effectiveness of internal control over financial reporting of Emergent BioSolutions Inc. and subsidiaries included in this Annual Report (Form 10-K) of Emergent BioSolutions Inc. and subsidiaries for the year ended December 31, 2016.
/s/ Ernst & Young LLP
McLean, Virginia
February 27, 2017